MARKET

IMUX

IMUX

Immunic Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.45
-0.09
-1.19%
After Hours: 7.44 -0.01 -0.13% 18:11 03/27 EDT
OPEN
7.74
PREV CLOSE
7.54
HIGH
8.06
LOW
7.45
VOLUME
50.69K
TURNOVER
--
52 WEEK HIGH
46.80
52 WEEK LOW
4.190
MARKET CAP
80.05M
P/E (TTM)
-2.0307
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of IMUX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average IMUX stock price target is 46.00 with a high estimate of 50.00 and a low estimate of 40.00.

EPS

IMUX News

More
  • TWO, ARI, GOGO and TTOO among midday movers
  • Seeking Alpha - Article · 4d ago
  • The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates
  • Benzinga · 03/18 11:36
  • Immunic, Inc. Reports Year End 2019 Financial Results and Highlights Recent Achievements
  • PR Newswire · 03/16 21:01
  • Immunic (IMUX) Presents At SVB Leerink Global Healthcare Conference - Slideshow
  • Seeking Alpha - Article · 03/03 22:08

Industry

Biotechnology & Medical Research
-2.43%
Pharmaceuticals & Medical Research
-0.87%

Hot Stocks

Symbol
Price
%Change

About IMUX

Immunic, Inc., formerly Vital Therapies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing oral therapies for the treatment of chronic inflammatory and autoimmune diseases. The Company is developing three small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. The Company’s lead development program, IMU-838, is in Phase II clinical development for ulcerative colitis and relapsing-remitting multiple sclerosis, with an additional Phase II trial in Crohn’s disease.
More

Webull offers kinds of Immunic Inc stock information, including NASDAQ:IMUX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMUX stock news, and many more online research tools to help you make informed decisions.